Edward Rapp - AbbVie Independent Director
| 4AB Stock | EUR 153.42 0.48 0.31% |
Director
Mr. Edward J. Rapp is an Independent Director of the Company. Mr. Rapp served as the Caterpillar Inc. group president for resource industries from 2014 until his retirement in mid2016. He previously served at Caterpillar as group president based in Singapore in 2013 and 2014 and as the chief financial officer from 2010 to 2013, and he was named a group president in 2007 since 2013.
| Age | 60 |
| Tenure | 11 years |
| Phone | 847 932 7900 |
| Web | https://www.abbvie.com |
Edward Rapp Latest Insider Activity
Tracking and analyzing the buying and selling activities of Edward Rapp against AbbVie stock is an integral part of due diligence when investing in AbbVie. Edward Rapp insider activity provides valuable insight into whether AbbVie is net buyers or sellers over its current business cycle. Note, AbbVie insiders must abide by specific rules, including filing SEC forms every time they buy or sell AbbVie'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Edward Rapp over two weeks ago Acquisition by Edward Rapp of 212 shares of AbbVie at 182.1 subject to Rule 16b-3 |
AbbVie Management Efficiency
The company has return on total asset (ROA) of 0.0991 % which means that it generated a profit of $0.0991 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7239 %, meaning that it generated $0.7239 on every $100 dollars invested by stockholders. AbbVie's management efficiency ratios could be used to measure how well AbbVie manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Shantanu Narayen | Pfizer Inc | 54 | |
| Daniel Cronin | Intel | N/A | |
| Suzanne Johnson | Pfizer Inc | 60 | |
| Wyllie Cornwell | Pfizer Inc | 70 | |
| Don Cornwell | Pfizer Inc | 69 | |
| Frances Fergusson | Pfizer Inc | 71 | |
| Patrick Gottschalk | Superior Plus Corp | 54 | |
| Scott Gottlieb | Pfizer Inc | N/A | |
| Robert Engbloom | Superior Plus Corp | 64 | |
| Randall Findlay | Superior Plus Corp | 67 | |
| Catherine Best | Superior Plus Corp | 64 | |
| David Smith | Superior Plus Corp | 59 | |
| James Smith | Pfizer Inc | 58 | |
| Mary Jordan | Superior Plus Corp | 58 | |
| Eugene Bissell | Superior Plus Corp | 64 | |
| Dan Littman | Pfizer Inc | 65 | |
| Stephen Sanger | Pfizer Inc | 69 | |
| Walentin Mirosh | Superior Plus Corp | 71 | |
| Ronald Blaylock | Pfizer Inc | 58 | |
| James Kilts | Pfizer Inc | 70 | |
| Helen Hobbs | Pfizer Inc | 65 | |
Management Performance
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 |
AbbVie Inc Leadership Team
Elected by the shareholders, the AbbVie's board of directors comprises two types of representatives: AbbVie inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AbbVie. The board's role is to monitor AbbVie's management team and ensure that shareholders' interests are well served. AbbVie's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AbbVie's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Carlos Alban, Executive Vice President - Commercial Operations | ||
| Robert Michael, Vice President Controller | ||
| Jeffrey Stewart, Senior Vice President U.S. Commercial Operations | ||
| Brett Hart, Independent Director | ||
| William Chase, Executive Vice President CFO | ||
| Roxanne Austin, Independent Director | ||
| Perry Siatis, Gen VP | ||
| Azita SalekiGerhardt, Senior Vice President - Operations | ||
| Scott Reents, VP CFO | ||
| Edward Rapp, Independent Director | ||
| Richard Gonzalez, Chairman of the Board, CEO | ||
| Brian Durkin, Vice President Controller | ||
| Thomas Hurwich, Vice President Controller | ||
| Frederick Waddell, Independent Director | ||
| Robert Alpern, Independent Director | ||
| Thomas Hudson, VP Officer | ||
| Glenn Tilton, Lead Independent Director | ||
| Henry Gosebruch, Executive Vice President Chief Strategy Officer | ||
| Elizabeth Shea, VP Relations | ||
| Rebecca Roberts, Independent Director | ||
| Edward Liddy, Independent Director | ||
| William Burnside, Independent Director | ||
| Timothy Richmond, Senior Vice President - Human Resources | ||
| Nicholas Donoghoe, Senior Vice President - Enterprise Innovation | ||
| Laura Schumacher, Executive Vice President - Business Development, External Affairs, General Counsel | ||
| Roy Roberts, Independent Director | ||
| Michael Severino, Executive Vice President - Research & Development, Chief Scientific Officer | ||
| Melody Meyer, Director |
AbbVie Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AbbVie a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 331.38 B | |||
| Shares Outstanding | 1.77 B | |||
| Shares Owned By Insiders | 0.12 % | |||
| Shares Owned By Institutions | 71.51 % | |||
| Price To Earning | 22.27 X | |||
| Price To Book | 18.07 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards AbbVie in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, AbbVie's short interest history, or implied volatility extrapolated from AbbVie options trading.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AbbVie Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |